Sumitomo Mitsui Trust Group Inc. Has $206.32 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,049,912 shares of the medical research company’s stock after acquiring an additional 26,648 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.58% of IQVIA worth $206,318,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the third quarter worth about $27,000. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. boosted its holdings in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. boosted its holdings in IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 99 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Trading Down 0.9 %

NYSE IQV opened at $208.13 on Friday. The firm has a market capitalization of $37.78 billion, a P/E ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. The business has a fifty day simple moving average of $200.53 and a 200 day simple moving average of $219.80. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. On average, analysts predict that IQVIA Holdings Inc. will post 10.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Redburn Atlantic assumed coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Bank of America dropped their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.